Miransertib is a pan-Akt inhibitor used in preclinical studies for PI3K-driven tumors (Yu et al., 2015), and the application of this drug is being evaluated in the treatment of other disease models, such as vascular malformations (Kobialka et al., 2021 preprint). Here, AKT1 is linked to vascular malformation.